The collaboration will leverage Orionis’s advanced Allo‑Glue™ platform and its AI‑driven discovery engine June 10th 2026, BOSTON, MA and GHENT, Belgium – Orionis Biosciences, a privately held, clinical-stage life sciences company pioneering proximity-induced therapeutic modalities, today announced a multi-year collaboration with Novartis to discover and design molecular glue drugs for challenging therapeutic targets across multiple…
News
Orionis Biosciences Appoints Dr. Giulio Draetta as Chief Strategy Officer
Orionis Biosciences announces appointment of Dr. Giulio Draetta as Chief Strategy Officer amid a period of strong pipeline growth….
Orionis Biosciences Announces Strategic Partnership with Genentech to Discover and Develop Molecular Glue Class Medicines for Cancer
Orionis Biosciences has announced a second collaboration with Genentech, worth $105 million upfront and up to $2 billion in potential milestone payments, to develop small-molecule glue medicines for oncology targets….
Orionis Biosciences Announces First Patient Dosed in Phase 1 Clinical Trial of ORB-011 in Patients with Advanced Solid Tumors
Dose-escalation study to evaluate ORB-011 as single agent, with initial safety, pharmacokinetic and mechanism-based pharmacodynamic readouts. Tony Fadell, inventor of the iPod, co-inventor of the iPhone, founder of Nest, and Principal at Build Collective, joins Orionis Board of Directors. November 15, 2023, BOSTON, MA, and GHENT, Belgium – Orionis Biosciences, a life sciences company pioneering…
Orionis Biosciences Announces Collaboration with Genentech to Discover and Develop Molecular Glue Class Medicines
Orionis to receive $47 million upfront, as well as future milestone-related payments. Orionis will leverage its Allo-Glue™ platform for discovery of small molecule monovalent glues. September 20, 2023, BOSTON, MA and GHENT, Belgium – Orionis Biosciences, a privately held life sciences company with an integrated drug discovery and chemical biology platform, announced today a multi-year…
Orionis Biosciences Presents Preclinical Data on Interferon and IL-2 Targeted Cytokine Immunotherapies for Cancer
Boston, MA & Ghent, Belgium – Orionis Biosciences, a life sciences company pioneering innovation of highly selective and tunable therapeutics for cancer and beyond, today presented preclinical data supporting its A-Kine™ platform for rational design of cis-acting immuno-cytokines at the 14th Annual PEGS Europe Protein & Antibody Engineering Summit, taking place November 14 – 16…